Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial.

"Conflict-of-interest statement: Pacheco-Barcia V: Advisory role: Advanced accelerator applications, a Novartis company. Speakers’ bureau: Merck, Eli Lilly, Eisai, Pierre Fabre. Congress attendance: Merck, Amgen, Merck Sharp and Dhome, Nutricia. Grant support: FSEOM and Merck. Other: Amgen. Martín AJM: Consultant or advisory role: GSK, Sanofi, Pfizer-BMS, Celgene, Leo Pharma, Incyte, Astra Zeneca, MSD, Lilly, Servier, Bayer, Roche. Research funding: Leo Pharma, Sanofi, Celgene. Speakers’ bureau: Rovi, Bayer, Menarini, Stada, Daichii Sankyo. Patents, Royalties. Other intellectual property: Risk assessment model in venous thromboembolism in cancer patients. Other authors declare no conflicts of interest related to this study."

"Conflict-of-interest statement: Pacheco-Barcia V: Advisory role: Advanced accelerator applications, a Novartis company. Speakers’ bureau: Merck, Eli Lilly, Eisai, Pierre Fabre. Congress attendance: Merck, Amgen, Merck Sharp and Dhome, Nutricia. Grant support: FSEOM and Merck. Other: Amgen. Martín AJM: Consultant or advisory role: GSK, Sanofi, Pfizer-BMS, Celgene, Leo Pharma, Incyte, Astra Zeneca, MSD, Lilly, Servier, Bayer, Roche. Research funding: Leo Pharma, Sanofi, Celgene. Speakers’ bureau: Rovi, Bayer, Menarini, Stada, Daichii Sankyo. Patents, Royalties. Other intellectual property: Risk assessment model in venous thromboembolism in cancer patients. Other authors declare no conflicts of interest related to this study."